493 related articles for article (PubMed ID: 21077702)
21. A conceptual approach to the masking effect of measures of disproportionality.
Maignen F; Hauben M; Hung E; Holle LV; Dogne JM
Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):208-17. PubMed ID: 24243699
[TBL] [Abstract][Full Text] [Related]
22. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
23. Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France.
Pariente A; Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N;
Drug Saf; 2012 Oct; 35(10):855-64. PubMed ID: 22967190
[TBL] [Abstract][Full Text] [Related]
24. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
Shamloo BK; Chhabra P; Freedman AN; Potosky A; Malin J; Weiss Smith S
Drug Saf; 2012 Jun; 35(6):507-18. PubMed ID: 22612854
[TBL] [Abstract][Full Text] [Related]
25. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.
Hochberg AM; Pearson RK; O'Hara DJ; Reisinger SJ
Drug Saf; 2009; 32(2):137-46. PubMed ID: 19236120
[TBL] [Abstract][Full Text] [Related]
26. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
[TBL] [Abstract][Full Text] [Related]
27. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.
Khadem TM; van Manen RP; Brown J
Pharmacotherapy; 2014 Dec; 34(12):1324-9. PubMed ID: 25421400
[TBL] [Abstract][Full Text] [Related]
28. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
[TBL] [Abstract][Full Text] [Related]
30. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
[TBL] [Abstract][Full Text] [Related]
31. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
[TBL] [Abstract][Full Text] [Related]
32. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
[TBL] [Abstract][Full Text] [Related]
33. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
[TBL] [Abstract][Full Text] [Related]
34. An Implementation and Visualization of the Tree-Based Scan Statistic for Safety Event Monitoring in Longitudinal Electronic Health Data.
Schachterle SE; Hurley S; Liu Q; Petronis KR; Bate A
Drug Saf; 2019 Jun; 42(6):727-741. PubMed ID: 30617498
[TBL] [Abstract][Full Text] [Related]
35. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
36. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
[TBL] [Abstract][Full Text] [Related]
37. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
38. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
39. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
[TBL] [Abstract][Full Text] [Related]
40. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
